Clinical trials: Amyloid Beta-protein
Alzheimer's Disease
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.
- Trial name
- NCT02576639
- Testing
- CNP520
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Down Syndrome, Amyloid Beta-protein
Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
To determine the sensitivity of the visual assessment of BAY94-9172 PET images in detecting cerebral β-amyloid in individuals with Down Syndrome (DS) and specificity in individuals without DS.
- Trial name
- NCT00928304
- Testing
- Florbetaben (BAY94-9172)
- Where
- 2 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer's Disease
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral and global domains based on the different applicable psychometric batteries and scales.
- Trial name
- AMBAR (NCT01561053)
- Testing
- Albumin 5%, Albumin 20%, Immunoglobulin
- Where
- 40 sites in United States, Spain
- Volunteers
- 347 people
- Sponsor
- Instituto Grifols, S.A.
Amyloid-beta
Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) through modulation of the sleep-wake cycle.
- Trial name
- NCT02063217
- Testing
- Sodium Oxybate, Sleep deprivation
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Amyloid-beta
Sleep Quality and Amyloid-Beta Kinetics
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) by modification of sleep efficiency.
- Trial name
- NCT03077620
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Amyloid Beta Protein
Escitalopram Effects on CSF Amyloid Beta
Alzheimers disease (AD) is a devastating illness, estimated to affect 5 million patients in the United States alone and projected to increase dramatically over the next decades as the population ages unless preventive measures…
- Trial name
- NCT02161458
- Testing
- Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks
- Where
- 2 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimer's Disease
Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease
The overall goal of this double-blind Phase II study is to evaluate the safety, efficacy and biological mechanisms of action of Intravenous Immunoglobulin (IVIg) in the treatment of mild to moderate stage Alzheimer's disease…
- Trial name
- NCT00299988
- Testing
- Intravenous Immunoglobulin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Weill Medical College of Cornell University
Alzheimer Disease, Amyloid Beta-Protein
Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients
The aim of the study is to investigate whether Florbetaben (BAY94-9172)positron emission tomography (PET) is able to distinguish between subjects with mild cognitive impairment (MCI) progressing to Alzheimer's disease (AD) from…
- Trial name
- NCT01138111
- Testing
- Florbetaben (BAY94-9172)
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- Lantheus Biosciences Ltd.
Hypertension
Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)
The aim of this study is to determine if lowering blood pressure using FDA approved medication (antihypertensive drugs) alters brain pulsatility and reduces brain amyloid beta protein accumulation in older adults.
- Trial name
- HIPAC (NCT03354143)
- Testing
- Standard Care, Intensive Treatment
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Alzheimer Disease
Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
We are studying subjects with mild to moderate Alzheimer's disease who have been on a stable dose of any cholinesterase inhibitor [donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne)] for at least 3 months, and…
- Trial name
- NCT00551161
- Testing
- memantine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwell Health
Alzheimer Disease
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
To determine the sensitivity and specificity of the visual assessment of tracer uptake in the Florbetaben PET images compared to histological verification of the presence or absence of cerebral β-amyloid in the respective…
- Trial name
- NCT01020838
- Testing
- Florbetaben (BAY94-9172)
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer Disease, Amyloid Beta-Protein
Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission…
- Trial name
- NCT00750282
- Testing
- Florbetaben (BAY94-9172)
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 422 people
- Sponsor
- Lantheus Biosciences Ltd.
Mild Cognitive Impairment
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease…
- Trial name
- CEDAR (NCT02646982)
- Testing
- Candesartan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Emory University